CFDA发文:近90%的中成药需改说明书!

2017-12-28 钱 瑜 北京商报

为加强注册管理,规范中成药规格表述,食药监总局于12月25日印发了《中成药规格表述技术指导原则》。

12月25日,国家食药监总局发布《中成药规格表述技术指导原则》(以下简称《指导原则》)指出,对已上市中成药规格的规范,将通过国家标准的制修订工作及上市后变更补充申请等逐步进行。根据《指导原则》,市场上约有90%中成药的说明书需要修改。

目前,中成药规格存在规格表述用语不规范、不统一;规格与用法用量关联性不强;相同品种规格标示不统一等问题。据了解,中成药大部分为复方制剂,因成分多且复杂,活性成分不明确而具有特殊性。当前上市品种中,绝大部分中药制剂规格不能标示产品活性成分,尽管通过标准整顿、国家统一药品批准文号等工作,大部分中成药标准标注了规格,但也有一些标注不规范,甚至部分文号未标注规格。

资料显示,药品规格是药品标准及说明书的重要内容。药品规格的正确表述是在药品流通经营过程中,正确表示药品数量和价格的基础。同时,在临床用药时计算准确的给药量,保证用药的安全有效,有着重要意义。中药规格标示的不规范,给药品监管、研发、使用、价格、招标等造成一些误用或误解。例如,中药规格的变更申请一直是中药药学补充申请的主要申请事项,在药品审评中,因规格不合理而不批准或要求补充资料的情况较为普遍。此外,当前市场上的中成药,仅以单位制剂的重量或体积等表述的占大多数,这给临床准确用药带来不便。

国家食药监总局表示,规格的重要性决定了规格表述应尽可能提供准确、清晰的药物成分及剂量信息,告知相关机构、医师及公众,以便对药品进行合理销售、贮运、分发、使用及监督检验。根据要求,中成药的药品规格标示内容中一般应包含单位制剂中所相当的处方药味(包括饮片、提取物、有效成分等)的理论量(或标示量),明确中成药规格表述应遵循与处方药味相对应,与用法用量、包装规格相协调,用语规范的原则。《指导原则》中指出,技术指导原则发布前已经受理的及发布后新受理的中药新药、属于国家食药监总局审批的上市后变更补充申请,均应根据此技术指导原则的要求规范表述中成药规格。

相关统计数据显示,目前已上市品种中,存在31种规格表述方式。其中单剂量药品的重量或装量的表达方式占70%以上,无规格者占15%。近90%的中药文号在说明书【规格】项下并没有标示单剂量药品的含药量,而是以重量、装量等来标示规格,不符合药品规格应该具备的内容。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=299139, encodeId=cefd2991395c, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160304/IMG56D94856B1B5D6405.jpg, createdBy=27931687771, createdName=一个字-牛, createdTime=Sat Mar 24 06:26:10 CST 2018, time=2018-03-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1890689, encodeId=701c18906894b, content=<a href='/topic/show?id=a867452008' target=_blank style='color:#2F92EE;'>#CFDA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4520, encryptionId=a867452008, topicName=CFDA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1a19115, createdName=stfoxst, createdTime=Fri Sep 28 19:21:00 CST 2018, time=2018-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1507162, encodeId=b719150e16234, content=<a href='/topic/show?id=18849189139' target=_blank style='color:#2F92EE;'>#说明书#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91891, encryptionId=18849189139, topicName=说明书)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3da79876963, createdName=yangpeizhi, createdTime=Sat Dec 30 10:21:00 CST 2017, time=2017-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=273434, encodeId=bd952e343495, content=说明中成药还是不规范, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzcjoLTEEgkSSQ8pVIiaf4a4INaoMLBV16QEk3dvvBRpicwIwmDGv0jePErJ4aE9ibVBDPtkialQLT9Bs/0, createdBy=04811949400, createdName=邓启付, createdTime=Fri Dec 29 07:29:43 CST 2017, time=2017-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=273327, encodeId=6c262e332756, content=好资料学习了!, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=92191944782, createdName=thlabcde, createdTime=Thu Dec 28 22:40:33 CST 2017, time=2017-12-28, status=1, ipAttribution=)]
    2018-03-24 一个字-牛

    学习了谢谢分享

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=299139, encodeId=cefd2991395c, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160304/IMG56D94856B1B5D6405.jpg, createdBy=27931687771, createdName=一个字-牛, createdTime=Sat Mar 24 06:26:10 CST 2018, time=2018-03-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1890689, encodeId=701c18906894b, content=<a href='/topic/show?id=a867452008' target=_blank style='color:#2F92EE;'>#CFDA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4520, encryptionId=a867452008, topicName=CFDA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1a19115, createdName=stfoxst, createdTime=Fri Sep 28 19:21:00 CST 2018, time=2018-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1507162, encodeId=b719150e16234, content=<a href='/topic/show?id=18849189139' target=_blank style='color:#2F92EE;'>#说明书#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91891, encryptionId=18849189139, topicName=说明书)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3da79876963, createdName=yangpeizhi, createdTime=Sat Dec 30 10:21:00 CST 2017, time=2017-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=273434, encodeId=bd952e343495, content=说明中成药还是不规范, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzcjoLTEEgkSSQ8pVIiaf4a4INaoMLBV16QEk3dvvBRpicwIwmDGv0jePErJ4aE9ibVBDPtkialQLT9Bs/0, createdBy=04811949400, createdName=邓启付, createdTime=Fri Dec 29 07:29:43 CST 2017, time=2017-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=273327, encodeId=6c262e332756, content=好资料学习了!, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=92191944782, createdName=thlabcde, createdTime=Thu Dec 28 22:40:33 CST 2017, time=2017-12-28, status=1, ipAttribution=)]
    2018-09-28 stfoxst
  3. [GetPortalCommentsPageByObjectIdResponse(id=299139, encodeId=cefd2991395c, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160304/IMG56D94856B1B5D6405.jpg, createdBy=27931687771, createdName=一个字-牛, createdTime=Sat Mar 24 06:26:10 CST 2018, time=2018-03-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1890689, encodeId=701c18906894b, content=<a href='/topic/show?id=a867452008' target=_blank style='color:#2F92EE;'>#CFDA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4520, encryptionId=a867452008, topicName=CFDA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1a19115, createdName=stfoxst, createdTime=Fri Sep 28 19:21:00 CST 2018, time=2018-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1507162, encodeId=b719150e16234, content=<a href='/topic/show?id=18849189139' target=_blank style='color:#2F92EE;'>#说明书#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91891, encryptionId=18849189139, topicName=说明书)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3da79876963, createdName=yangpeizhi, createdTime=Sat Dec 30 10:21:00 CST 2017, time=2017-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=273434, encodeId=bd952e343495, content=说明中成药还是不规范, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzcjoLTEEgkSSQ8pVIiaf4a4INaoMLBV16QEk3dvvBRpicwIwmDGv0jePErJ4aE9ibVBDPtkialQLT9Bs/0, createdBy=04811949400, createdName=邓启付, createdTime=Fri Dec 29 07:29:43 CST 2017, time=2017-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=273327, encodeId=6c262e332756, content=好资料学习了!, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=92191944782, createdName=thlabcde, createdTime=Thu Dec 28 22:40:33 CST 2017, time=2017-12-28, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=299139, encodeId=cefd2991395c, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160304/IMG56D94856B1B5D6405.jpg, createdBy=27931687771, createdName=一个字-牛, createdTime=Sat Mar 24 06:26:10 CST 2018, time=2018-03-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1890689, encodeId=701c18906894b, content=<a href='/topic/show?id=a867452008' target=_blank style='color:#2F92EE;'>#CFDA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4520, encryptionId=a867452008, topicName=CFDA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1a19115, createdName=stfoxst, createdTime=Fri Sep 28 19:21:00 CST 2018, time=2018-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1507162, encodeId=b719150e16234, content=<a href='/topic/show?id=18849189139' target=_blank style='color:#2F92EE;'>#说明书#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91891, encryptionId=18849189139, topicName=说明书)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3da79876963, createdName=yangpeizhi, createdTime=Sat Dec 30 10:21:00 CST 2017, time=2017-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=273434, encodeId=bd952e343495, content=说明中成药还是不规范, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzcjoLTEEgkSSQ8pVIiaf4a4INaoMLBV16QEk3dvvBRpicwIwmDGv0jePErJ4aE9ibVBDPtkialQLT9Bs/0, createdBy=04811949400, createdName=邓启付, createdTime=Fri Dec 29 07:29:43 CST 2017, time=2017-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=273327, encodeId=6c262e332756, content=好资料学习了!, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=92191944782, createdName=thlabcde, createdTime=Thu Dec 28 22:40:33 CST 2017, time=2017-12-28, status=1, ipAttribution=)]
    2017-12-29 邓启付

    说明中成药还是不规范

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=299139, encodeId=cefd2991395c, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160304/IMG56D94856B1B5D6405.jpg, createdBy=27931687771, createdName=一个字-牛, createdTime=Sat Mar 24 06:26:10 CST 2018, time=2018-03-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1890689, encodeId=701c18906894b, content=<a href='/topic/show?id=a867452008' target=_blank style='color:#2F92EE;'>#CFDA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4520, encryptionId=a867452008, topicName=CFDA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1a19115, createdName=stfoxst, createdTime=Fri Sep 28 19:21:00 CST 2018, time=2018-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1507162, encodeId=b719150e16234, content=<a href='/topic/show?id=18849189139' target=_blank style='color:#2F92EE;'>#说明书#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91891, encryptionId=18849189139, topicName=说明书)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3da79876963, createdName=yangpeizhi, createdTime=Sat Dec 30 10:21:00 CST 2017, time=2017-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=273434, encodeId=bd952e343495, content=说明中成药还是不规范, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzcjoLTEEgkSSQ8pVIiaf4a4INaoMLBV16QEk3dvvBRpicwIwmDGv0jePErJ4aE9ibVBDPtkialQLT9Bs/0, createdBy=04811949400, createdName=邓启付, createdTime=Fri Dec 29 07:29:43 CST 2017, time=2017-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=273327, encodeId=6c262e332756, content=好资料学习了!, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=92191944782, createdName=thlabcde, createdTime=Thu Dec 28 22:40:33 CST 2017, time=2017-12-28, status=1, ipAttribution=)]
    2017-12-28 thlabcde

    好资料学习了!

    0

相关资讯

中成药迎来新变化!总局发文规范中成药规格表述

10月11日,国家食品药品监督管理总局公开征求《中成药规格表述技术指导原则(征求意见稿)》意见。

CFDA:中成药名禁用宝灵精 公众普遍接受者可不改名

新的通用名称批准后,给予2年过渡期,过渡期内采取新名称后括注老名称的方式,让患者和医生逐步适应。

90%中成药,要改说明书

昨日(12月25日),国家食药监总局发布《中成药规格表述技术指导原则》,按照指导原则要求,至少90%的中成药要修改说明书。

食药监总局:中成药命名要科学简明、避免夸大疗效

据国家食品药品监督管理总局网站消息,国家食品药品监督管理总局发布《关于发布中成药通用名称命名技术指导原则的通告》,同时下发《关于规范已上市中成药通用名称命名的通知》。两个文件明确提出中成药命名要坚持科学简明、避免重名,规范命名、避免夸大疗效,体现传统文化特色的原则。

重点监控下的中成药和辅助用药的突围之道(上)

在2017年岁末,医药市场也像进入了冷冬,虽然偶有阳光,但也无法化解阵阵寒风给行业带来的“寒意”。这段时间,药企变相商业贿赂被罚、“神药”广告被警告、各个省市出台停用或修改各类辅助用药,行业重大事件频出。特别是辅助用药政策,很多医院面临医保的巨大压力,采取一刀切措施,停用所有的辅助用药,其中不乏过十亿的大品种。广州也重点监控67种药品,也包括喜炎平等大品种在列。另外,受到莎普爱思事件的

大控药!医院通知,每次只能开1盒!

近日,业界流传一份广州某医院的通知,在7月15日广州医改开始后,医院嘱咐门诊医生在物价改革后,关于挂号费、诊疗费变化,以及计算医生提成的等相关事宜。